Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07207122 · ClinicalTrials.gov registry record · NA

Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases

A NA study of Parkinson Disease and Mild Cognitive Impairment, sponsored by Sanmai Technologies PBC dba Sanmai.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT07207122: Recruiting NA study of Parkinson Disease and Mild Cognitive Impairment, sponsored by Sanmai Technologies PBC dba Sanmai.

NCT07207122 is a NA study of Parkinson Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Sanmai Technologies PBC dba Sanmai. The registered enrollment target is 20 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07207122, a NA study of Parkinson Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Sanmai Technologies PBC dba Sanmai.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and efficacy of transcranial focused ultrasound neuromodulation in improving neural function, cognitive and behavioral performance, and quality of life for patients with neurodegenerative diseases.

Primary Outcome

The MDS-UPDRS Part III is a clinician-administered assessment of motor function in Parkinson's disease. It includes 18 items with 33 individual ratings, each scored from 0 (normal) to 4 (severe), with a total score range of 0 to 132. Higher scores indicate worse motor impairment. Assessments will be conducted in the OFF-medication state by trained, blinded raters using standardized procedures. The outcome measure is defined as the change from baseline in total score at post-treatment milestones

Interventions

  • DEVICE Transcranial focused ultrasound modulation administered to a region involved in disease pathology.

Study Locations (1)

California

  • The Regenesis Project - Santa Monica

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-10-08
Est. Completion 2026-08
Phase NA

What NCT07207122 shows while recruiting

NCT07207122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).

The record links to 7 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Transcranial focused ultrasound modulation administered to a region involved in disease pathology. is the first listed.

NCT07207122 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07207122 about?

NCT07207122 is a clinical study titled "Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases". The purpose of this study is to evaluate the safety and efficacy of transcranial focused ultrasound neuromodulation in improving neural function, cognitive and behavioral performance, and quality of life for patients with neurodegenerative diseases.

What is the current status of trial NCT07207122?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-10-08. Estimated completion is 2026-08.

What conditions does trial NCT07207122 study?

This clinical trial studies the following conditions: Parkinson Disease, Mild Cognitive Impairment, Parkinson's Disease (PD), Alzheimer's Disease (AD), Parkinson's Disease Dementia (PDD).

What interventions are being tested in trial NCT07207122?

The interventions under investigation include: Transcranial focused ultrasound modulation administered to a region involved in disease pathology. (DEVICE).

Who is sponsoring clinical trial NCT07207122?

This trial is sponsored by Sanmai Technologies PBC dba Sanmai, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07207122 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07207122's enrollment target sits among peer trials

20 241st of 297 higher than 46 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07207122, the US trial registry maintained by the National Library of Medicine. NCT07207122 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.